Basal cell carcinoma of skin of other and unspecified parts of face
ICD-10 C44.31 is a billable code used to indicate a diagnosis of basal cell carcinoma of skin of other and unspecified parts of face.
Basal cell carcinoma (BCC) is the most common form of skin cancer, primarily arising from the basal cells in the epidermis. This specific code, C44.31, is used for BCC located on the skin of other and unspecified parts of the face, which may include areas not specifically categorized under more defined facial regions. BCC is often linked to chronic sun exposure, leading to mutations in the DNA of skin cells. Clinically, BCC presents as a pearly or waxy bump, a flat, flesh-colored lesion, or a scar-like area. Surgical excision is the primary treatment, with the goal of achieving clear surgical margins to minimize recurrence. Reconstruction may be necessary depending on the size and location of the excised lesion, particularly in cosmetically sensitive areas of the face. The prognosis for BCC is generally excellent, with a low risk of metastasis, but careful monitoring and follow-up are essential due to the potential for local recurrence.
Detailed descriptions of the lesion, including size, location, and histological findings.
Diagnosis and treatment of BCC, follow-up visits for monitoring, and management of surgical complications.
Ensure accurate documentation of the surgical technique used and any reconstruction performed.
Comprehensive treatment plans, including chemotherapy or radiation if applicable, and follow-up care.
Management of advanced BCC cases or those requiring multidisciplinary approaches.
Document any systemic therapies or clinical trials being considered.
Used when excising a BCC from the face.
Document the size of the lesion and margins.
Dermatologists should ensure detailed operative notes.
The primary treatment for basal cell carcinoma is surgical excision, often using Mohs micrographic surgery to ensure clear margins.
